Breaking AI & Tech News Analyzed

Jeffrey Stephen Wigand, a biochemist who helped reveal how tobacco companies targeted children and hid the addictive nature of cigarettes, has been drawing parallels between the tobacco industry and social media companies. Wigand, who played a crucial role in the landmark tobacco trials of the 1990s, believes that social media companies have similarly designed their products to be addictive, particularly targeting children.The recent verdict in a major social media trial, which found Meta and YouTube liable for their role in creating addictive products, has strengthened comparisons to the legal crackdown on big tobacco. Wigand sees it as a similar situation, where companies prioritize profits over people's well-being. He notes that both industries use advertisements to target children, with social media companies using data to create addictive algorithms.Wigand's experience in the tobacco industry informs his perspective on social media. He was hired by Brown & Williamson (B&W;) in 1989 to develop a safer cigarette but was fired after raising concerns about carcinogenic substances in cigarettes. He then publicly declared that the tobacco industry was a 'nicotine delivery business' and helped the federal government in its investigations.Wigand believes that social media companies, like tobacco companies, intentionally addict people, especially children, to generate revenue. He emphasizes that brain development in children makes them vulnerable to addiction, and that social media companies exploit this vulnerability.The tobacco industry faced significant reforms and financial penalties following Wigand's whistleblowing. He hopes that similar actions will be taken against social media companies, including putting guardrails on access for children and holding companies accountable for their role in creating harm. Wigand's message to tech workers considering becoming whistleblowers is to carefully weigh the personal costs and prepare for the challenges that come with speaking out.

The film 'All the President's Men', directed by Alan Pakula and starring Robert Redford and Dustin Hoffman, premiered 50 years ago on Saturday at the John F Kennedy Center for the Performing Arts. The movie is based on the 1974 book of the same name by Washington Post reporters Bob Woodward and Carl Bernstein, which chronicled their investigation into the Watergate imbroglio that led to the downfall of President Richard Nixon. The film was a critical and commercial success, earning eight Oscar nominations and winning four, including best adapted screenplay for William Goldman and best supporting actor for Jason Robards as Ben Bradlee, the Post editor. The movie is widely regarded as a classic of American cinema and a landmark in the genre of journalism films. Jane Alexander, who played the role of Judy Hoback, the 'Bookkeeper' of the Committee to Re-elect the President, recalls her experience filming the iconic scene with Hoffman and Redford. She praises Pakula's direction and the attention to detail that went into recreating the Post's newsroom. The film's accuracy and attention to detail were indeed a hallmark of its production. Woodward and Bernstein worked closely with the filmmakers to ensure that the story was told accurately, and the production team went to great lengths to recreate the Post's office and the Washington D.C. of the 1970s. The article also touches on the impact of the film on the careers of its stars and the journalists it portrayed. Redford and Hoffman spent months researching and rehearsing their roles, and their performances are widely praised. Woodward reflects on the film's portrayal of him and its impact on his personal life. The anniversary of the film comes at a time when the media is under attack and the Washington Post, now owned by tech billionaire Jeff Bezos, has recently undergone significant changes. The film's themes of investigative journalism and the importance of a free press remain as relevant today as they were 50 years ago.

The UK government's new employment rights watchdog, the Fair Work Agency (FWA), is set to launch on Tuesday, but its priorities have already faced criticism from worker advocates. The agency, a cornerstone of Labour's Employment Rights Act, will bring together several existing labour enforcement bodies and focus on policing the minimum wage, holiday pay, and modern slavery. However, the government's priorities for the FWA's first year have been criticized for focusing on reducing regulatory burdens on businesses, rather than taking a more robust approach to protecting workers' rights. The priorities, listed by Matthew Taylor, the incoming chair of the FWA, include 'thought leadership' and 'reducing regulatory burdens'. Worker advocates argue that this approach risks turning the agency into 'a dead duck' before it even begins. Sharon Graham, the general secretary of Unite, which represents over 1 million workers, said that the priorities showed the agency was 'in danger of being a dead duck before it even begins'. She added that the government needs to urgently ensure that the FWA focuses on bringing rogue bosses to heel, rather than seeking ways to allow dodgy companies to continue bad behaviour. The UK has among the fewest labour inspectors per worker within Organisation for Economic Co-operation and Development countries, with different estimates putting the scale of unpaid wages in the billions of pounds. This means employers face 'no credible threat of inspection, investigation or enforcement', according to Prof David Whyte of Queen Mary University. A report to be published on Monday by the Institute of Employment Rights will recommend adequate funding, unannounced inspections, and prosecutions for wrongdoing. The government has yet to announce the budget it will allocate to the FWA. A government spokesperson said: 'The new Fair Work Agency will end the current fragmented system of enforcing employment rights, making it easier for workers and victims of exploitation to get the rights they're entitled to. The agency will take tough action against businesses that deliberately flout the law while supporting employers who want to do the right thing and strengthen workers' rights.'

A United States federal judge has rejected a motion from the Department of Justice to reconsider his earlier ruling dismissing subpoenas against Jerome Powell, the chairman of the Federal Reserve.In a six-page opinion published on Friday, Judge James Boasberg reaffirmed his decision to nullify the subpoenas, stating that they were issued for an 'improper purpose': to pressure Powell into compliance with President Donald Trump's demands.The subpoenas were part of an investigation into Powell's handling of renovations to the Federal Reserve's historic buildings in Washington, DC, which have gone over budget. The Trump administration has accused Powell of 'malfeasance' and called for his premature resignation.Boasberg criticized the Trump administration's efforts, saying they presented 'no evidence whatsoever of fraud' and that the subpoenas were an attempt to undermine the Federal Reserve's independence.The ruling is likely to set the stage for the Trump administration to appeal, with US Attorney Jeanine Pirro previously denying any political motivation for the investigation.

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

A devastating incident unfolded at the Alejandro Villanueva Stadium in Lima, Peru, on Friday, claiming the life of one person and injuring dozens more. The event, which was a 'flag-waving' gathering, took place a day before a highly anticipated derby match between Alianza Lima and Universitario de Deportes.The Peruvian health minister, Juan Carlos Velasco Guerrero, confirmed the death and reported that 47 people were injured, with three in critical condition. Initial reports suggested that parts of the stadium's wall had collapsed, but officials later clarified that there were no structural failures.Alianza Lima expressed condolences for the casualties and pledged to cooperate fully with authorities to investigate the incident. The club promised 'total transparency' in the investigation.The Peruvian professional soccer league announced that Saturday's match would proceed as planned, emphasizing its commitment to ensuring safe environments for spectators. The league will continue to work closely with clubs and authorities to promote safety and wellbeing at sporting events.The Alejandro Villanueva Stadium, also known as Matute, was built in the 1970s and has a capacity of over 33,900 seats. Despite limited modernization, the stadium remains a 'fairly basic ground,' according to The Stadium Guide.

Ten years after the groundbreaking Panama Papers investigation, the revelations about hidden offshore accounts and shell companies continue to reverberate across the globe. The leak, which exposed the financial maneuvers of politicians, celebrities, and corporations, sparked a wave of regulatory scrutiny and public demand for greater transparency. In the decade since, governments have introduced stricter anti‑money‑laundering rules and enhanced reporting standards, yet the challenge of tracking illicit wealth persists. Analysts note that the papers highlighted systemic weaknesses in the international financial system, prompting ongoing debates about the balance between privacy and accountability. Beyond policy changes, the Panama Papers underscored the power of investigative journalism to uncover complex financial networks. Their legacy endures as journalists and watchdog groups continue to probe offshore activities, reinforcing the role of a free press in safeguarding democratic institutions. As the world reflects on this milestone, the conversation has shifted from the initial shock of the disclosures to a broader assessment of how such leaks shape global financial governance and influence future reforms.

President Donald Trump announced on Truth Social that Pam Bondi is being removed as Attorney General, ending a contentious 14‑month stint at the Justice Department. Bondi, who described her upcoming shift to the private sector as a "transition," will leave the post within the next month. In a rapid reshuffle, Trump elevated Deputy Attorney General Todd Blanche—who previously served as the former president’s criminal‑defense lawyer—to acting attorney general. The president also hinted that EPA Administrator Lee Zeldin could become the permanent replacement, signaling a continued preference for close allies in key legal roles. Bondi’s ouster follows a series of high‑profile controversies. Most notably, her management of the Jeffrey Epstein files drew intense scrutiny. After promising full transparency, the Justice Department released heavily redacted documents that failed to satisfy public and congressional demands for a "client list" and other evidence. Critics, including victims’ attorney Gloria Allred, called her departure "long overdue" for mishandling the files. Beyond the Epstein saga, Bondi struggled to deliver the political prosecutions Trump expected. Efforts to pursue former FBI Director James Comey and other officials linked to investigations of the president stalled or collapsed, fueling Trump’s frustration that she was not "weaponising" the department aggressively enough against his perceived enemies. Bondi, a former Florida attorney general and the state’s first female AG, built a reputation on tough‑on‑crime initiatives such as combating human trafficking and cracking down on "pill mills." However, her limited involvement in the original Epstein non‑prosecution deal and her heated exchange with a Democratic lawmaker—where she called him a "washed‑up loser"—further eroded confidence in her leadership. The White House confirmed that Bondi’s private‑sector role will be announced "in the near future," while Blanche issued a statement on X thanking Trump for the trust placed in him and pledging to "continue backing the blue, enforcing the law, and keeping America safe." Congressional oversight intensifies as the House Oversight Committee had scheduled Bondi to appear before it on April 14 to answer questions about the Epstein documents. With her exit, committee chair James Comer said Republicans would deliberate whether to pursue the subpoena, while Democrats, led by Robert Garcia, insist she "will not escape accountability." Reactions span the political spectrum: Democrats such as Senator Elizabeth Warren denounced the DOJ under Bondi as a "cesspool of corruption," whereas Republican Senator Chuck Grassley praised her responsiveness to oversight and noted a decline in violent crime during her tenure. Republican Thomas Massie urged the next AG to release all Epstein files and pursue arrests. As the administration searches for a permanent attorney general, the choice between Blanche and Zeldin will signal how closely Trump intends to align the Justice Department with his political agenda moving forward.

Recently obtained footage shows the aftermath of aerial strikes that destroyed a bridge in Iran. The video, which has been making rounds in media circles, provides a visual testament to the significant damage incurred by the region's infrastructure. The bridge, a crucial connectivity link, was completely destroyed in the strikes, raising concerns about the humanitarian and economic implications for the local population. While specific details about the strikes, including the perpetrators and the exact date, remain scarce, the footage underscores the severity of the situation in the region. The incident has sparked international attention, with many calling for an investigation into the circumstances surrounding the strikes and their impact on civilian life. As the situation continues to unfold, the international community remains on high alert, monitoring developments and assessing the broader implications for regional stability.